Jerusalem Venture Partners (JVP) and pharma giant AstraZeneca have selected 9 companies for 6-month program, turning start-ups into groundbreaking companies
Selected companies will help meet post-COVID-19 demand for increased digital and remote healthcare. Solutions include AI-based patient care; remote patient monitoring
The companies will present their solutions on Wednesday 13 May at JVP’s Jerusalem offices, the first such event since the corona outbreak
Wednesday 13 May (Jerusalem) – As health systems across the world face unprecedented post-corona challenges, Jerusalem Venture Partners (JVP), pharmaceutical giant AstraZeneca (which is working with an Oxford University research team to develop a large-scale COVID-19 vaccine) and the ii2020 National Initiative today launched the PlayBeyondBio program. From hundreds of applicants, nine companies developing potentially groundbreaking products, have been selected – docdok.health, bio-T, Serenus.AI, Biobeat, TimeStamp, Flaskdata.io, Resmetrix, DiA Imaging Analysis and IDEA Bio-Medical. The companies will gather today at the offices of JVP in Jerusalem, to present their products in the first tech gathering of its kind in the city since the corona outbreak.
The selected startups will participate in a six-month fast track mentoring and development program, which will help them define their vision, identify potential markets, develop marketing strategies and technological integration. Specifically, AstraZeneca experts will advise in areas of development, regulation and sales, while JVP will provide expertise in business strategy and investment opportunities. In addition, Microsoft for Startups will help with employee recruitment and provide access to tools and databases. These strategic partners will accompany the participating companies through all stages of the process, including product development, adapting to global market needs, plus possible commercial arrangements and investment.
Companies were selected for the PlayBeyondBio program based on their value proposition, ability to verify and apply it, and the need for their proposed solution. The PlayBeyondBio program will operate in collaboration with Microsoft, Cisco, Kahn-Sagol Maccabi Research Innovation Institute and Sha’are Zedek Medical Center.
“PlayBeyondBio is a revolution in the development of Israeli digital healthcare start-ups, which have the potential to change the rules of the game,” said Erel Margalit, Founder and Chairman of JVP, adding, “During these early stages of a company’s development, we are bringing together all the relevant pieces in one business development platform – Entrepreneurs, investors, customers and the healthcare system. Israel today has the opportunity to become a global leader in digital healthcare innovation. Israeli entrepreneurs have the ability to lead this revolution.
“By combining groundbreaking Israeli technology with the knowledge and expertise of a global pharma giant like AstraZeneca, plus other partners such as Microsoft, the ii2020 National Initiative, Maccabi Healthcare and Israel’s leading hospitals, we are providing the solid infrastructure to build successful companies, with the potential to be the next big thing in digital health.”
Ohad Goldberg, CEO of AstraZeneca Israel said, “For over a decade, AstraZeneca has been operating locally, to provide access to pharmaceuticals and invest in clinical research in Israel. We are proud to launch PlayBeyondBio, a unique program which recognizes Israel as an emerging force in digital health innovation. AstraZeneca, alongside the program’s strategic partners, will support the development of medical solutions which give the health system better tools to address the needs of patients, not only in this country but across the world.”
The companies selected to participate in PlayBeyondBio:
Biobeat – With the acute need for remote medical services in a post-corona world, Biobeat is developing a cutting-edge wearable for remote non-invasive medical-grade monitoring of vital signs including blood pressure, heart rate, respiratory rate, saturation, and temperature, as well as more complex parameters.
Flaskdata.io – Drug and vaccine development, including those for COVID-19, require thorough medical experiments which often take substantial time. Flaskdata.io’s real-time clinical trial platform significantly reduces the amount of time it takes to perform medical experiments using AI technology.
Serenus.AI – In order to help reduce the number of unnecessary surgeries and medical prescriptions, Serenus.AI’s patented AI-based platform was developed to empower patients and medical professionals at critical post-diagnostic crossroads, advancing the quality of medical care while saving valuable resources.
Docdok.health – The ‘Netflix of healthcare,’ docdok.health helps monitor symptoms when a patient is not under direct medical supervision. Docdok.health develops disease-specific apps, which monitor symptoms, alert when there is deterioration and monitors drug treatment.
TimeStamp – Too many patients fail to take their medication responsibly, potentially endangering life. TimeStamp has developed an electronic smart sticker product that records usage history, especially for asthma sufferers, and is adaptable to most inhalers without requiring patient engagement.
DiA Imaging Analysis – Ultrasounds for pregnant women today rely upon the skill and experience of medical professionals performing the test. DiA has developed an AI-based technology that allows clinicians with all levels of experience to identify abnormalities that are otherwise difficult to find visually.
IDEA Bio-Medical – IDEA Bio-Medical has developed an AI-powered precision oncological decision support system, which significantly improves the ability to analyze biopsies and make decisions regarding cancer treatment.
Resemetrix – Currently, deterioration is often detected too late in those suffering from respiratory conditions, leading to severe complications and hospitalization. Resmetrix is developing a unique wearable system wirelessly connected to a smartphone app, that accurately monitors respiratory patterns of at-risk patients in real-time.
Bio-T – Bio-T provides a cloud platform built especially for medical device manufacturers. Its software enables medical device manufacturers to quickly upgrade any standalone device to an online ‘medical device as a service’ providing remote care.
——————— ENDS ————————
Jerusalem Venture Partners (JVP), founded and led by Dr. Erel Margalit, is an internationally renowned venture capital fund. JVP has to date raised $1.4 billion across nine funds, and has been listed numerous times by Preqin, and other rankings, as one of the top-ten consistently performing VC firms worldwide. JVP has built over 140 companies, leveraging a broad network of partners and market expertise to help companies become global market leaders. JVP was recently chosen by New York City and EDC to lead the cyber security cyber hub in NYC. Among the pioneering firms of the Israeli venture capital industry, JVP has been instrumental in building some of the largest companies out of Israel, facilitating 12 Initial Public Offerings on NASDAQ, including CyberArk Software (NASDAQ: CYBR, $4.7 billion mkt. cap.), QLIK Technologies (NASDAQ: QLIK, then $4 billion mkt. cap.) and Cogent Communications (NASDAQ: CCOI, $3 billion mkt. cap.) and more.
AstraZeneca is a leading, international, innovation-driven pharmaceutical company that initiates and promotes the research, development and marketing of innovative prescription drugs. The company operates in a number of core areas including cancer, cardiovascular, metabolic and respiratory diseases, in which the company has developed breakthrough drugs. The company operates in over 100 countries around the world and in 2007 AstraZeneca Israel was established as the official representative of the international company in the country. In Israel, the company invests in research and treatment development, promotes and encourages clinical research and works with health organizations to strengthen the health services provided in Israel for the benefit of the public as a whole.